Functional Foods and Nutraceuticals to Reduce the Risk of Cardiometabolic Disease: Where We Are, and Where We Are Going

Federica Fogacci,Claudio Borghi,Arrigo Francesco Giuseppe Cicero

DOI: https://doi.org/10.3390/nu16183152

IF: 5.9

2024-09-18

Nutrients

Abstract:Atherosclerotic cardiovascular diseases (ASCVDs) remain leading causes of mortality and disability in Western countries [...].

What problem does this paper attempt to address?

The Possible Role of Nutraceuticals in the Prevention of Cardiovascular Disease

Angela Albarosa Rivellese,Paola Ciciola,Giuseppina Costabile,Claudia Vetrani,Marilena Vitale

DOI: https://doi.org/10.1007/s40292-019-00309-5

2019-02-27

Abstract:Cardiovascular diseases (CVDs) are the main causes of mortality and disability worldwide. Although the initial therapeutic approach to improve the main cardiovascular (CV) risk factors is based on nonpharmacological measures, mainly lifestyle modifications, compliance to recommendations is often poor and inadequate. Therefore, in recent years the use of several nutraceuticals, i.e., nutrients and/or bioactive compounds of plant or microbial origin with potentially healthful effects, has become widespread. However, to date, the scientific data on the possible benefits of the use of nutraceuticals are still inconclusive, due to the absence of adequately controlled intervention studies at least for some of them. Against this background, the scientific evidence derived from controlled intervention studies in relation to the effects of some nutraceuticals (i.e. fiber, phytosterols, soy products, red yeast rice, polyphenols and berberine) on the main CV risk factors (body weight, blood pressure, blood glucose levels and plasma lipids) in humans will be reviewed.
Functional Food and Cardiovascular Disease Prevention and Treatment: A Review

Sedigheh Asgary,Ali Rastqar,Mahtab Keshvari

DOI: https://doi.org/10.1080/07315724.2017.1410867

Abstract:Cardiovascular disease (CVD) is now the leading cause of death globally and is a growing health concern. Lifestyle factors, including nutrition, play an important role in the etiology and treatment of CVD. Functional foods based on their basic nutritional functions can decrease the risk of many chronic diseases and have some physiological benefits. They contain physiologically active components either from plant or animal sources, marketed with the claim of their ability to reduce heart disease risk, focusing primarily on established risk factors, which are hyperlipidemia, diabetes, metabolic syndrome, obesity/overweight, elevated lipoprotein A level, small dense low-density lipoprotein cholesterol (LDL-C), and elevated inflammatory marker levels. Functional foods are suspected to exert their cardioprotective effects mainly through blood lipid profile level and improve hypertension control, endothelial function, platelet aggregation, and antioxidant actions. Clinical and epidemiological observations indicate that vegetable and fruit fiber, nuts and seeds, sea foods, coffee, tea, and dark chocolate have cardioprotective potential in humans, as well whole-grain products containing intact grain kernels rich in fiber and trace nutrients. They are nutritionally more important because they contain phytoprotective substances that might work synergistically to reduce cardiovascular risk. This review will focus on the reciprocal interaction between functional foods and the potential link to cardiovascular health and the possible mechanisms of action.
Recent advances in precision nutrition and cardiometabolic diseases

Miguel A Martínez-González,Francisco J Planes,Miguel Ruiz-Canela,Estefanía Toledo,Ramón Estruch,Jordi Salas-Salvadó,Rafael Valdés-Más,Pedro Mena,Olga Castañer,Montse Fitó,Clary Clish,Rikard Landberg,Clemens Wittenbecher,Liming Liang,Marta Guasch-Ferré,Rosa M Lamuela-Raventós,Dong D Wang,Nita Forouhi,Cristina Razquin,Frank B Hu

DOI: https://doi.org/10.1016/j.rec.2024.09.003

2024-09-30

Abstract:A growing body of research on nutrition omics has led to recent advances in cardiovascular disease epidemiology and prevention. Within the PREDIMED trial, significant associations between diet-related metabolites and cardiovascular disease were identified, which were subsequently replicated in independent cohorts. Some notable metabolites identified include plasma levels of ceramides, acyl-carnitines, branched-chain amino acids, tryptophan, urea cycle pathways, and the lipidome. These metabolites and their related pathways have been associated with incidence of both cardiovascular disease and type 2 diabetes. Future directions in precision nutrition research include: a) developing more robust multimetabolomic scores to predict long-term risk of cardiovascular disease and mortality; b) incorporating more diverse populations and a broader range of dietary patterns; and c) conducting more translational research to bridge the gap between precision nutrition studies and clinical applications.
Popular functional foods and nutraceuticals with lipid lowering activity and in relation to cardiovascular disease, dyslipidemia, and related complications: an overview

K. Venkatakrishnan,Chin-Kun Wang,H. Chiu,You-Cheng Shen

DOI: https://doi.org/10.31665/JFB.2018.2137

2018-06-30

Journal of Food Bioactives

Abstract:Cardiovascular disease (CVD) is the most common non-communicable ailment which claims one-third of total global death. This contribution provides an overview of cardiovascular diseases (CVDs), hypercholesterolemia and hyperlipidemia (dyslipidemia) and their related complications as well as the current treatment options with special attention to popular functional foods and nutraceuticals. Currently, many synthetic lipid-lowering drugs are available in the market. However, they trigger several adverse effects. Thus, to overcome this problem nutraceuticals and functional foods which are considered safe, and with multifaceted lipid-lowering activity are highly recommended (adjuvant therapy) for treating dyslipidemia. This review intends to shed light on how to choose the appropriate or better nutraceutical/functional food ingredients to alleviate the risk of CVD, based on recent literature survey with the inclusion of clinical trials and meta-analysis to ensure the efficacy of nutraceuticals/ functional foods on lipid profile.

Agricultural and Food Sciences,Medicine
Lipid-lowering nutraceuticals update on scientific evidence

Giuseppe Derosa,Alessandro Colletti,Pamela Maffioli,Angela D'Angelo,Alessandro Lupi,Giovanni B Zito,Gian Francesco Mureddu,Riccardo Raddino,Francesco Fedele,Arrigo F G Cicero,Angela D’Angelo,Giovanni B. Zito,Arrigo F.G. Cicero

DOI: https://doi.org/10.2459/jcm.0000000000000970

IF: 2.43

2020-07-06

Journal of Cardiovascular Medicine

Abstract:Cardiovascular diseases (CVDs) are the main cause of mortality worldwide. Risk factors of CVD can be classified into modifiable (smoking, hypertension, diabetes, hypercholesterolemia) through lifestyle changes or taking drug therapy and not modifiable (age, ethnicity, sex and family history). Elevated total cholesterol (TC) and low-density lipoprotein-cholesterol (LDL-C) levels have a lead role in the development of coronary heart disease (CHD), while high levels of high-density lipoprotein-cholesterol (HDL-C) seem to have a protective role.

cardiac & cardiovascular systems
The Cardioprotective Effects of Nutritional Ketosis: Mechanisms and Clinical Implications

Claudia Venturini,Lucia Mancinelli,Giulia Matacchione,Fabiola Olivieri,Roberto Antonicelli

DOI: https://doi.org/10.3390/nu16234204

IF: 5.9

2024-12-05

Nutrients

Abstract:Cardiovascular diseases (CVDs) persist as the primary cause of death worldwide, accounting for roughly 17.9 million fatalities each year. The prevalence of obesity, metabolic syndrome, and type 2 diabetes (key risk factors for CVD) continues to escalate at an alarming rate, necessitating novel therapeutic strategies to address this global health crisis. Nutritional ketosis, induced through ketogenic diets, modified fasting, intermittent fasting, and medium-chain triglyceride (MCT) oil consumption, has garnered attention for its potential cardioprotective effects. Ketosis is a metabolic state in which the body, due to a significantly reduced intake of carbohydrates, shifts its primary energy source from glucose to ketone bodies, i.e., beta-hydroxybutyrate (BHB), acetoacetate, and acetone, which are produced in the liver from fatty acids. This review examines the mechanisms by which ketone bodies, particularly BHB, mitigate cardiovascular risk. We focus mainly on the anti-inflammatory and antioxidative properties of BHB and summarize recent evidence to highlight the clinical relevance of ketosis in cardiometabolic health.

nutrition & dietetics
Gut Microbiota and Cardiovascular Disease: Evidence on the Metabolic and Inflammatory Background of a Complex Relationship

A. Di Giorgio,L. Santoro,A. Nesci,A. Santoliquido,Alessia D'Alessandro,Vittorio Ruggieri,A. Gasbarrini,Claudia Carnuccio,F. Ponziani

DOI: https://doi.org/10.3390/ijms24109087

IF: 5.6

2023-05-01

International Journal of Molecular Sciences

Abstract:Several studies in recent years have demonstrated that gut microbiota–host interactions play an important role in human health and disease, including inflammatory and cardiovascular diseases. Dysbiosis has been linked to not only well-known inflammatory diseases, such as inflammatory bowel diseases, rheumatoid arthritis, and systemic lupus erythematous, but also to cardiovascular risk factors, such as atherosclerosis, hypertension, heart failure, chronic kidney disease, obesity, and type 2 diabetes mellitus. The ways the microbiota is involved in modulating cardiovascular risk are multiple and not only related to inflammatory mechanisms. Indeed, human and the gut microbiome cooperate as a metabolically active superorganism, and this affects host physiology through metabolic pathways. In turn, congestion of the splanchnic circulation associated with heart failure, edema of the intestinal wall, and altered function and permeability of the intestinal barrier result in the translocation of bacteria and their products into the systemic circulation, further enhancing the pro-inflammatory conditions underlying cardiovascular disorders. The aim of the present review is to describe the complex interplay between gut microbiota, its metabolites, and the development and evolution of cardiovascular diseases. We also discuss the possible interventions intended to modulate the gut microbiota to reduce cardiovascular risk.

Medicine,Biology,Environmental Science
Role of nutrition and healthy lifestyle, for individuals in primary prevention: recent data, gaps in evidence and future directions

Theodora Metsovitis,Marco Bernardi,Eric Bruckert,Federica Fogacci,Arrigo Cicero,Sebastian Garcia-Zamora,Luigi Spadafora,Denis Angoulvant,Giuseppe Biondi-Zoccai,Pierre Sabouret

DOI: https://doi.org/10.5114/aoms/187841

2024-04-30

Archives of Medical Science

Abstract:All recent guidelines on cardiovascular prevention have highlighted the role of healthy diet and lifestyle advocating holistic approach to reduce cardiovascular burden among population. Despite these efforts, registries have reported that only a minority of healthcare professionals provide advice on diet and lifestyle, and, in most cases, counseling is suboptimal for several reasons. Cardiovascular benefits linked to lifestyle and nutrition seem to be underestimated by many patients and doctors. This overview aims to summarize well-established benefits related to lifestyle and nutrition, discuss the current debates in this field in order to improve awareness among the medical community and to promote a better implementation of non-pharmaceutical measures to prevent the occurrence of atherothrombotic events.

medicine, general & internal
[Cardiovascular risk and cardiometabolic risk: an epidemiological evaluation]

Diego Vanuzzo,Lorenza Pilotto,Renata Mirolo,Salvatore Pirelli

Abstract:On the basis of a critical literature review, this article deals with the concepts of global cardiovascular risk and cardiometabolic risk, pointing out their links but also their unresolved issues and discussing their usefulness in clinical practice. The global cardiovascular risk is the probability of suffering from a coronary event or stroke in a given period of time and in this sense it is an absolute risk, generally reported as percentage at 10 years. Usually risk functions are used, derived from longitudinal studies of healthy people at baseline. They consider some factors that are coherently linked with events in population analyses: among these there are some metabolic factors (total cholesterol, HDL cholesterol, fasting blood glucose), some biological factors (blood pressure) and some lifestyle factors (tobacco smoking), all modifiable beyond those non-modifiable like age and gender. The chosen factors must be independent at multivariate analysis, simple and standardized to measure, and contribute to significantly increase the risk-function predictivity. To be reliable, these risk functions must be derived from the same population where they will be later administered. For this reason the Italian Progetto CUORE, in the longitudinal study section, built a database of risk factors from longitudinal comparable studies started between the mid '80s and '90s and followed up the participants for cardiovascular mortality and morbidity to estimate the Italian global cardiovascular risk (first coronary or cerebrovascular event) for men and women. Two tools have been produced, the risk charts and a score software (see www.cuore.iss.it). The ongoing epidemics of obesity and diabetes and the fact that diabetes is associated with classical risk factors like hypertension and dyslipidemia induced the American Diabetes Association and the American Heart Association to launch a "call to action" to prevent both cardiovascular disease and diabetes. In this paper, as cardiometabolic risk factors were considered those "closely related to diabetes and cardiovascular disease: fasting/postprandial hyperglycemia, overweight/obesity, elevated systolic and diastolic blood pressure, and dyslipidemia". The association among the cardiometabolic risk factors has been known for a long time, and much of their etiology has been ascribed to insulin resistance. Also, the fact that these "metabolic" abnormalities can cluster in many individuals gave rise to the term "metabolic syndrome", a construct embraced by many organizations but questioned by other authors. From an epidemiological point of view the metabolic syndrome seems to increase modestly the cardiovascular risk, whereas in non-diabetic individuals it predicts diabetes much more efficiently. Many studies have compared the performance of the classical cardiovascular evaluation tools (the Framingham risk score, the SCORE charts, the Progetto CUORE score) and metabolic syndrome in cardiovascular disease prediction. Usually in people at high risk the presence of the metabolic syndrome does not improve the risk, whereas in people at lower risk its presence increases significantly the chances of cardiovascular disease. Many studies have shown that positive lifestyle interventions markedly reduce the rate of progression of type 2 diabetes. Also some drugs were tested for diabetes prevention, usually in people with impaired glucose tolerance. Oral diabetes drugs considered together (acarbose, metformin, flumamine, glipizide, phenformin) were less effective than lifestyle interventions, with different results among the drugs; the antiobesity drug orlistat gave similar results to lifestyle interventions. In Italy an appropriate approach to cardiovascular disease and diabetes prevention may be that of first evaluating the global cardiovascular risk using the charts or the score software of the Progetto CUORE, because high-risk subjects (> or =20%) must be treated aggressively independently of the presence of the metabolic syndrome; as a second step the metabolic syndrome may be sought, because it increases the risk; finally some attention should be paid to non-diabetic hyperglycemic individuals.
Nutraceuticals with lipid-lowering activity: do they have any effect beyond cholesterol reduction?

Arrigo FG Cicero,Elisa Tartagni,Claudio Borghi,Arrigo Fg Cicero

DOI: https://doi.org/10.2217/clp.12.55

2012-10-01

Clinical Lipidology

Abstract:A large number of nutraceuticals with lipid-lowering activity are currently available on the market, however, for most of them, it is not known whether the lipid-lowering activity is associated with a concrete reduction in cardiovascular disease risk. The aim of this review is to evaluate whether the most commonly used lipid-lowering nutraceuticals (i.e., soluble fibers, phytosterols, garlic, soy proteins, monacolins, policosanols, berberine and n-3 fatty acids) also have some positive effects on other cardiovascular disease risk factors, on instrumental biomarkers of cardiovascular disease risk or the risk of cardiovascular events. Beyond red yeast rice and n-3 fatty acids, whose use was related to a significant and reliable decrease in cardiovascular disease morbidity and mortality, no evidence is available that demonstrates a preventive effect of lipid-lowering nutraceuticals on hard cardiovascular outcomes. However, for berberine and soluble fibers, the evidence of a positive multimetabolic effect is ...
Functional Food and Bioactive Compounds on the Modulation of the Functionality of HDL-C: A Narrative Review

Karla Paulina Luna-Castillo,Sophia Lin,José Francisco Muñoz-Valle,Barbara Vizmanos,Andres López-Quintero,Fabiola Márquez-Sandoval

DOI: https://doi.org/10.3390/nu13041165

IF: 5.9

2021-04-01

Nutrients

Abstract:Cardiovascular diseases (CVD) remain a serious public health problem and are the primary cause of death worldwide. High-density lipoprotein cholesterol (HDL-C) has been identified as one of the most important molecules in the prevention of CVD due to its multiple anti-inflammatories, anti-atherogenic, and antioxidant properties. Currently, it has been observed that maintaining healthy levels of HDL-C does not seem to be sufficient if the functionality of this particle is not adequate. Modifications in the structure and composition of HDL-C lead to a pro-inflammatory, pro-oxidant, and dysfunctional version of the molecule. Various assays have evaluated some HDL-C functions on risk populations, but they were not the main objective in some of these. Functional foods and dietary compounds such as extra virgin olive oil, nuts, whole grains, legumes, fresh fish, quercetin, curcumin, ginger, resveratrol, and other polyphenols could increase HDL functionality by improving the cholesterol efflux capacity (CEC), paraoxonase 1 (PON1), and cholesteryl ester transfer protein (CETP) activity. Nevertheless, additional rigorous research basic and applied is required in order to better understand the association between diet and HDL functionality. This will enable the development of nutritional precision management guidelines for healthy HDL to reduce cardiovascular risk in adults. The aim of the study was to increase the understanding of dietary compounds (functional foods and bioactive components) on the functionality of HDL.

nutrition & dietetics
Inflammation and Cardiovascular Disease: The Future

Natalie Arnold,Katharina Lechner,Christoph Waldeyer,Michael D Shapiro,Wolfgang Koenig

DOI: https://doi.org/10.15420/ecr.2020.50

2021-05-17

European Cardiology Review

Abstract:Despite considerable advances in reducing the global burden of atherosclerotic cardiovascular disease by targeting conventional risk factors, significant residual risk remains, with low-grade inflammation being one of the strongest risk modifiers. Inflammatory processes within the arterial wall or systemic circulation, which are driven in a large part by modified lipoproteins but subsequently trigger a hypercoagulable state, are a hallmark of atherosclerotic cardiovascular disease and, in particular, its clinical complications. Extending conventional guideline-based clinical risk stratification algorithms by adding biomarkers of inflammation may refine phenotypic screening, improve risk stratification and guide treatment eligibility in cardiovascular disease prevention. The integration of interventions aimed at lowering the inflammatory burden, alone or in combination with aggressive lipid-modifying or even antithrombotic agents, for those at high cardiovascular risk may hold the potential to reduce the still substantial burden of cardiometabolic disease. This review provides perspectives on future clinical research in atherosclerosis addressing the tight interplay between inflammation, lipid metabolism and thrombosis, and its translation into clinical practice.
Are Europeans moving towards dietary habits more suitable for reducing cardiovascular disease risk?

Gabriele Riccardi,Marilena Vitale,Olga Vaccaro

DOI: https://doi.org/10.1016/j.numecd.2020.07.018

2020-10-01

Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Aims</h3><p>Cardiovascular diseases are the main cause of death in Europe. Food choices represent the most important factors undermining health and well-being; they account for as much as half of all CVD deaths in Europe. The aim of this viewpoint is to evaluate food choices of the European population and their temporal trends in relation to possible effects on the cardiovascular disease risk.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Data Synthesis</h3><p>The CVD death rate attributable to diet-related factors has fallen in Europe over the last 25 years; however, the pace of the reduction has slowed down in the last ten years. In parallel, in the last decade unfavorable changes in the dietary habits associated with CVD risk have occurred.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>A mismatch exists between the available evidence on the health-promoting potential of the diet and the relatively modest and inconsistent improvements of dietary habits in the European population observed in recent years. Nutritional education alone will not be enough to improve the lifestyle of people in Europe. Policy options to be considered to reach this aim should necessarily include also initiatives for facilitating production, marketing, availability and affordability of healthy foods in each and every European country.</p>
What is the best diet for cardiovascular wellness? A comparison of different nutritional models

Silvia Migliaccio,Caterina Brasacchio,Francesca Pivari,Ciro Salzano,Luigi Barrea,Giovanna Muscogiuri,Silvia Savastano,Annamaria Colao,

DOI: https://doi.org/10.1038/s41367-020-0018-0

2020-07-01

International Journal of Obesity Supplements

Abstract:Cardiovascular diseases (CVD) represent to date the leading cause of mortality in both genders in the developed countries. In this context, a strong need for CVD prevention is emerging through lifestyle modification and nutrition. In fact, several studies linked CVD with unhealthy nutrition, alcohol consumption, stress, and smoking, together with a low level of physical activity. Thus, the primary aim is to prevent and reduce CVD risk factors, such as impaired lipid and glycemic profiles, high blood pressure and obesity. Different types of diet have been, therefore, established to optimize the approach regarding this issue such as the Mediterranean diet, Dietary Approaches to Stop Hypertension diet (DASH), vegetarian diet, ketogenic diet, and Japanese diet. Depending on the diet type, recommendations generally emphasize subjects to increase vegetables, fruits, whole grains, and pulses consumption, but discourage or recommend eliminating red meat, sweets, and sugar-sweetened beverages, along with processed foods that are high in sugar, salt, fat, or low in dietary fiber. In particular, we evaluated and compared the peculiar aspects of these well-known dietary patterns and, thus, this review evaluates the critical factors that increase CVD risk and the potential application and benefits of nutritional protocols to ameliorate dietary and lifestyle patterns for CVD prevention.
Pharmacology of Nutraceuticals with Lipid Lowering Properties

Andrea Poli,Francesco Visioli

DOI: https://doi.org/10.1007/s40292-019-00311-x

2019-03-15

Abstract:Lowering total and, in particular, LDL cholesterol reduces cardiovascular risk and clinical events. Cholesterol-lowering strategies are manifold. Better diets and positive lifestyle changes are the foremost approach; the use of functional foods, of food supplements/nutraceuticals, and pharmacological treatment must be considered in patients with increasing lipid abnormalities and or increasing cardiovascular risk. Here, we briefly review the most frequently occurring cholesterol-lowering substances found in functional foods or nutraceuticals, i.e. plant sterols and stanols, monacolin K found in red yeast rice, berberine and beta-glucans. We intentionally use a colloquial style to convey our message, which physicians can forward to their patients. We underscore that these preparations are effective either alone or in combination, but that patients should use them after careful discussion with primary care physicians or specialists.
Microbiota-derived short-chain fatty acids: Implications for cardiovascular and metabolic disease

Yingdong Lu,Yang Zhang,Xin Zhao,Chang Shang,Mi Xiang,Li Li,Xiangning Cui

DOI: https://doi.org/10.3389/fcvm.2022.900381

IF: 3.6

2022-08-12

Frontiers in Cardiovascular Medicine

Abstract:Cardiovascular diseases (CVDs) have been on the rise around the globe in the past few decades despite the existing guidelines for prevention and treatment. Short-chain fatty acids (SCFAs) are the main metabolites of certain colonic anaerobic bacterial fermentation in the gastrointestinal tract and have been found to be the key metabolites in the host of CVDs. Accumulating evidence suggest that the end-products of SCFAs (including acetate, propionate, and butyrate) interact with CVDs through maintaining intestinal integrity, anti-inflammation, modulating glucolipid metabolism, blood pressure, and activating gut-brain axis. Recent advances suggest a promising way to prevent and treat CVDs by controlling SCFAs. Hence, this review tends to summarize the functional roles carried out by SCFAs that are reported in CVDs studies. This review also highlights several novel therapeutic interventions for SCFAs to prevent and treat CVDs.

cardiac & cardiovascular systems
Carotenoids: potential allies of cardiovascular health?

Alessandra Gammone Maria,Riccioni Graziano,D’Orazio Nicolantonio

DOI: https://doi.org/10.3402/fnr.v59.26762

2015-01-01

Abstract:Carotenoids are a class of natural, fat-soluble pigments found principally in plants. They have potential antioxidant biological properties because of their chemical structure and interaction with biological membranes. Epidemiologic studies supported the hypothesis that antioxidants could be used as an inexpensive means of both primary and secondary cardiovascular disease (CVD) prevention. In fact, the oxidation of low-density lipoproteins (LDL) in the vessels plays a key role in the development of atherosclerotic lesions. The resistance of LDL to oxidation is increased by high dietary antioxidant intake, so that carotenoids, as part of food patterns such as the Mediterranean diet, may have beneficial effects on cardiovascular health too. Further properties of carotenoids leading to a potential reduction of cardiovascular risk are represented by lowering of blood pressure, reduction of pro-inflammatory cytokines and markers of inflammation (such as C-reactive protein), and improvement of insulin sensitivity in muscle, liver, and adipose tissues. In addition, recent nutrigenomics studies have focused on the exceptional ability of carotenoids in modulating the expression of specific genes involved in cell metabolism. The aim of this review is to focus attention to this effect of some carotenoids to prevent CVD.

food science & technology,nutrition & dietetics
Targeting Metabolic Diseases: The Role of Nutraceuticals in Modulating Oxidative Stress and Inflammation

Aida Dama,Kleva Shpati,Patricia Daliu,Seyma Dumur,Era Gorica,Antonello Santini

DOI: https://doi.org/10.3390/nu16040507

IF: 5.9

2024-02-11

Nutrients

Abstract:The escalating prevalence of metabolic and cardiometabolic disorders, often characterized by oxidative stress and chronic inflammation, poses significant health challenges globally. As the traditional therapeutic approaches may sometimes fall short in managing these health conditions, attention is growing toward nutraceuticals worldwide; with compounds being obtained from natural sources with potential therapeutic beneficial effects being shown to potentially support and, in some cases, replace pharmacological treatments, especially for individuals who do not qualify for conventional pharmacological treatments. This review delves into the burgeoning field of nutraceutical-based pharmacological modulation as a promising strategy for attenuating oxidative stress and inflammation in metabolic and cardiometabolic disorders. Drawing from an extensive body of research, the review showcases various nutraceutical agents, such as polyphenols, omega-3 fatty acids, and antioxidants, which exhibit antioxidative and anti-inflammatory properties. All these can be classified as novel nutraceutical-based drugs that are capable of regulating pathways to mitigate oxidative-stress- and inflammation-associated metabolic diseases. By exploring the mechanisms through which nutraceuticals interact with oxidative stress pathways and immune responses, this review highlights their potential to restore redox balance and temper chronic inflammation. Additionally, the challenges and prospects of nutraceutical-based interventions are discussed, encompassing bioavailability enhancement, personalized treatment approaches, and clinical translation. Through a comprehensive analysis of the latest scientific reports, this article underscores the potential of nutraceutical-based pharmacological treatment modulation as a novel avenue to fight oxidative stress and inflammation in the complex landscape of metabolic disorders, particularly accentuating their impact on cardiovascular health.

nutrition & dietetics
Non-Conventional Risk Factors: "Fact" or "Fake" in Cardiovascular Disease Prevention?

Giovanni Cimmino,Francesco Natale,Roberta Alfieri,Luigi Cante,Simona Covino,Rosa Franzese,Mirella Limatola,Luigi Marotta,Riccardo Molinari,Noemi Mollo,Francesco S Loffredo,Paolo Golino

DOI: https://doi.org/10.3390/biomedicines11092353

IF: 4.757

2023-08-24

Biomedicines

Abstract:Cardiovascular diseases (CVDs), such as arterial hypertension, myocardial infarction, stroke, heart failure, atrial fibrillation, etc., still represent the main cause of morbidity and mortality worldwide. They significantly modify the patients' quality of life with a tremendous economic impact. It is well established that cardiovascular risk factors increase the probability of fatal and non-fatal cardiac events. These risk factors are classified into modifiable (smoking, arterial hypertension, hypercholesterolemia, low HDL cholesterol, diabetes, excessive alcohol consumption, high-fat and high-calorie diet, reduced physical activity) and non-modifiable (sex, age, family history, of previous cardiovascular disease). Hence, CVD prevention is based on early identification and management of modifiable risk factors whose impact on the CV outcome is now performed by the use of CV risk assessment models, such as the Framingham Risk Score, Pooled Cohort Equations, or the SCORE2. However, in recent years, emerging, non-traditional factors (metabolic and non-metabolic) seem to significantly affect this assessment. In this article, we aim at defining these emerging factors and describe the potential mechanisms by which they might contribute to the development of CVD.

biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy

Functional Foods and Nutraceuticals to Reduce the Risk of Cardiometabolic Disease: Where We Are, and Where We Are Going

The Possible Role of Nutraceuticals in the Prevention of Cardiovascular Disease

Functional Food and Cardiovascular Disease Prevention and Treatment: A Review

Recent advances in precision nutrition and cardiometabolic diseases

Popular functional foods and nutraceuticals with lipid lowering activity and in relation to cardiovascular disease, dyslipidemia, and related complications: an overview

Lipid-lowering nutraceuticals update on scientific evidence

The Cardioprotective Effects of Nutritional Ketosis: Mechanisms and Clinical Implications

Gut Microbiota and Cardiovascular Disease: Evidence on the Metabolic and Inflammatory Background of a Complex Relationship

Role of nutrition and healthy lifestyle, for individuals in primary prevention: recent data, gaps in evidence and future directions

[Cardiovascular risk and cardiometabolic risk: an epidemiological evaluation]

Nutraceuticals with lipid-lowering activity: do they have any effect beyond cholesterol reduction?

Functional Food and Bioactive Compounds on the Modulation of the Functionality of HDL-C: A Narrative Review

Inflammation and Cardiovascular Disease: The Future

Are Europeans moving towards dietary habits more suitable for reducing cardiovascular disease risk?

What is the best diet for cardiovascular wellness? A comparison of different nutritional models

Pharmacology of Nutraceuticals with Lipid Lowering Properties

Microbiota-derived short-chain fatty acids: Implications for cardiovascular and metabolic disease

Carotenoids: potential allies of cardiovascular health?

Targeting Metabolic Diseases: The Role of Nutraceuticals in Modulating Oxidative Stress and Inflammation

Non-Conventional Risk Factors: "Fact" or "Fake" in Cardiovascular Disease Prevention?